AN2 Therapeutics To Reveal Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera At The SOHO 2026 Annual Meeting
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced
AN2 Therapeutics is showing new test results for a medicine it's developing to treat a blood disease called polycythemia vera at a big medical conference. When companies share positive research data, it can mean their medicine is progressing, but we won't know the full story until we hear what the data actually shows.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.